Globe Life (GL) Projected to Announce Quarterly Earnings on Wednesday

Globe Life (NYSE:GL) is anticipated to release its Q2 2026 results after the market closes on Wednesday, July 22nd. Analysts expect Globe Life to announce earnings of $3.67 per share and revenue of $1.5904 billion for the quarter. Globe Life has set its FY 2026 guidance at 15.400-15.90 EPS. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 23, 2026 at 11:00 AM ET.

Globe Life (NYSE:GL) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $3.43 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.46 by ($0.03). The company had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.56 billion. Globe Life had a net margin of 19.38% and a return on equity of 20.94%. Globe Life’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.07 earnings per share. On average, analysts expect Globe Life to post $16 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Globe Life Price Performance

Shares of NYSE:GL opened at $184.55 on Tuesday. The firm has a market capitalization of $14.33 billion, a price-to-earnings ratio of 12.76 and a beta of 0.47. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.07 and a quick ratio of 0.07. The business’s 50 day simple moving average is $167.16 and its 200-day simple moving average is $151.92. Globe Life has a 12 month low of $120.05 and a 12 month high of $191.55.

Globe Life Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Monday, July 6th will be paid a $0.33 dividend. This represents a $1.32 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Monday, July 6th. Globe Life’s dividend payout ratio (DPR) is presently 9.13%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Keefe, Bruyette & Woods lifted their price objective on Globe Life from $180.00 to $192.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. TD Cowen upped their target price on Globe Life from $199.00 to $215.00 and gave the company a “buy” rating in a report on Tuesday, June 23rd. Jefferies Financial Group raised their price target on Globe Life from $147.00 to $166.00 and gave the company a “hold” rating in a research report on Friday, July 10th. Truist Financial lifted their price target on Globe Life from $180.00 to $185.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Finally, Wells Fargo & Company boosted their price objective on shares of Globe Life from $172.00 to $193.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Globe Life currently has an average rating of “Moderate Buy” and an average target price of $184.60.

Insider Buying and Selling at Globe Life

In related news, CEO James Matthew Darden sold 4,663 shares of Globe Life stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $153.88, for a total transaction of $717,542.44. Following the completion of the transaction, the chief executive officer directly owned 58,451 shares in the company, valued at $8,994,439.88. The trade was a 7.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Frank M. Svoboda sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $156.68, for a total value of $3,133,600.00. Following the completion of the sale, the chief executive officer directly owned 54,020 shares in the company, valued at approximately $8,463,853.60. The trade was a 27.02% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 124,187 shares of company stock worth $19,529,414. 2.11% of the stock is currently owned by insiders.

Institutional Trading of Globe Life

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Compound Planning Inc. raised its stake in Globe Life by 4.3% in the 4th quarter. Compound Planning Inc. now owns 1,968 shares of the company’s stock valued at $275,000 after purchasing an additional 82 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Globe Life by 2.7% during the 4th quarter. Invesco Ltd. now owns 3,948,676 shares of the company’s stock worth $552,262,000 after purchasing an additional 102,445 shares during the last quarter. Strive Financial Group LLC purchased a new position in shares of Globe Life during the fourth quarter valued at approximately $1,974,000. Vident Advisory LLC boosted its position in Globe Life by 57.7% during the fourth quarter. Vident Advisory LLC now owns 19,650 shares of the company’s stock worth $2,748,000 after acquiring an additional 7,189 shares during the last quarter. Finally, EP Wealth Advisors LLC acquired a new stake in Globe Life during the fourth quarter worth approximately $470,000. 81.61% of the stock is currently owned by hedge funds and other institutional investors.

Globe Life Company Profile

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.